|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SHISA6 |
Gene summary for SHISA6 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SHISA6 | Gene ID | 388336 |
| Gene name | shisa family member 6 | |
| Gene Alias | SHISA6 | |
| Cytomap | 17p12 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q6ZSJ9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 388336 | SHISA6 | HTA11_866_3004761011 | Human | Colorectum | AD | 2.61e-43 | 1.67e+00 | 0.096 |
| 388336 | SHISA6 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.29e-74 | 2.02e+00 | 0.294 |
| 388336 | SHISA6 | A002-C-010 | Human | Colorectum | FAP | 1.59e-04 | 3.47e-01 | 0.242 |
| 388336 | SHISA6 | A001-C-207 | Human | Colorectum | FAP | 3.43e-03 | 4.80e-01 | 0.1278 |
| 388336 | SHISA6 | A015-C-203 | Human | Colorectum | FAP | 2.41e-07 | 5.78e-01 | -0.1294 |
| 388336 | SHISA6 | A001-C-119 | Human | Colorectum | FAP | 1.69e-16 | 9.11e-01 | -0.1557 |
| 388336 | SHISA6 | A001-C-108 | Human | Colorectum | FAP | 3.23e-03 | 4.85e-01 | -0.0272 |
| 388336 | SHISA6 | A002-C-021 | Human | Colorectum | FAP | 5.06e-47 | 1.16e+00 | 0.1171 |
| 388336 | SHISA6 | A001-C-104 | Human | Colorectum | FAP | 1.13e-14 | 6.44e-01 | 0.0184 |
| 388336 | SHISA6 | A015-C-005 | Human | Colorectum | FAP | 2.75e-10 | 6.40e-01 | -0.0336 |
| 388336 | SHISA6 | A015-C-106 | Human | Colorectum | FAP | 1.43e-19 | 7.96e-01 | -0.0511 |
| 388336 | SHISA6 | A015-C-104 | Human | Colorectum | FAP | 1.67e-11 | 6.43e-01 | -0.1899 |
| 388336 | SHISA6 | A001-C-014 | Human | Colorectum | FAP | 4.66e-05 | 4.19e-01 | 0.0135 |
| 388336 | SHISA6 | A001-C-203 | Human | Colorectum | FAP | 3.03e-07 | 5.43e-01 | -0.0481 |
| 388336 | SHISA6 | CRC-3-11773 | Human | Colorectum | CRC | 3.36e-14 | 6.24e-01 | 0.2564 |
| 388336 | SHISA6 | HTA12-25-1 | Human | Pancreas | PDAC | 3.65e-03 | 3.95e-01 | 0.313 |
| 388336 | SHISA6 | HTA12-26-1 | Human | Pancreas | PDAC | 9.17e-18 | 7.95e-01 | 0.3728 |
| 388336 | SHISA6 | HTA12-29-1 | Human | Pancreas | PDAC | 1.57e-20 | 5.66e-01 | 0.3722 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:1905475 | Colorectum | AD | regulation of protein localization to membrane | 73/3918 | 175/18723 | 3.37e-10 | 2.93e-08 | 73 |
| GO:0030111 | Colorectum | AD | regulation of Wnt signaling pathway | 102/3918 | 328/18723 | 8.51e-06 | 2.03e-04 | 102 |
| GO:0016055 | Colorectum | AD | Wnt signaling pathway | 130/3918 | 444/18723 | 1.60e-05 | 3.37e-04 | 130 |
| GO:0198738 | Colorectum | AD | cell-cell signaling by wnt | 130/3918 | 446/18723 | 2.02e-05 | 4.10e-04 | 130 |
| GO:0060070 | Colorectum | AD | canonical Wnt signaling pathway | 90/3918 | 303/18723 | 1.76e-04 | 2.38e-03 | 90 |
| GO:0060828 | Colorectum | AD | regulation of canonical Wnt signaling pathway | 77/3918 | 253/18723 | 2.19e-04 | 2.87e-03 | 77 |
| GO:0099173 | Colorectum | AD | postsynapse organization | 51/3918 | 168/18723 | 2.47e-03 | 1.90e-02 | 51 |
| GO:0050808 | Colorectum | AD | synapse organization | 112/3918 | 426/18723 | 4.25e-03 | 2.92e-02 | 112 |
| GO:0099072 | Colorectum | AD | regulation of postsynaptic membrane neurotransmitter receptor levels | 22/3918 | 62/18723 | 5.72e-03 | 3.64e-02 | 22 |
| GO:19054752 | Colorectum | MSS | regulation of protein localization to membrane | 68/3467 | 175/18723 | 2.16e-10 | 2.09e-08 | 68 |
| GO:00301112 | Colorectum | MSS | regulation of Wnt signaling pathway | 98/3467 | 328/18723 | 3.37e-07 | 1.36e-05 | 98 |
| GO:00160552 | Colorectum | MSS | Wnt signaling pathway | 124/3467 | 444/18723 | 6.06e-07 | 2.26e-05 | 124 |
| GO:01987382 | Colorectum | MSS | cell-cell signaling by wnt | 124/3467 | 446/18723 | 7.83e-07 | 2.77e-05 | 124 |
| GO:00600702 | Colorectum | MSS | canonical Wnt signaling pathway | 86/3467 | 303/18723 | 1.58e-05 | 3.56e-04 | 86 |
| GO:00608282 | Colorectum | MSS | regulation of canonical Wnt signaling pathway | 74/3467 | 253/18723 | 1.99e-05 | 4.26e-04 | 74 |
| GO:00991732 | Colorectum | MSS | postsynapse organization | 48/3467 | 168/18723 | 9.32e-04 | 9.44e-03 | 48 |
| GO:0030178 | Colorectum | MSS | negative regulation of Wnt signaling pathway | 48/3467 | 170/18723 | 1.23e-03 | 1.18e-02 | 48 |
| GO:00324091 | Colorectum | MSS | regulation of transporter activity | 78/3467 | 310/18723 | 2.09e-03 | 1.78e-02 | 78 |
| GO:00990721 | Colorectum | MSS | regulation of postsynaptic membrane neurotransmitter receptor levels | 21/3467 | 62/18723 | 2.87e-03 | 2.23e-02 | 21 |
| GO:0022898 | Colorectum | MSS | regulation of transmembrane transporter activity | 70/3467 | 278/18723 | 3.36e-03 | 2.54e-02 | 70 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SHISA6 | SNV | Missense_Mutation | rs760817325 | c.1166G>A | p.Arg389His | p.R389H | Q6ZSJ9 | protein_coding | deleterious(0) | probably_damaging(0.953) | TCGA-A2-A04U-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| SHISA6 | SNV | Missense_Mutation | c.712N>G | p.Ile238Val | p.I238V | Q6ZSJ9 | protein_coding | tolerated(0.24) | benign(0.018) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SHISA6 | SNV | Missense_Mutation | novel | c.1472G>A | p.Arg491His | p.R491H | Q6ZSJ9 | protein_coding | tolerated(0.8) | benign(0.011) | TCGA-LL-A7T0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SHISA6 | SNV | Missense_Mutation | c.691N>A | p.Glu231Lys | p.E231K | Q6ZSJ9 | protein_coding | deleterious(0.01) | possibly_damaging(0.879) | TCGA-FU-A3YQ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| SHISA6 | SNV | Missense_Mutation | novel | c.931N>A | p.Val311Ile | p.V311I | Q6ZSJ9 | protein_coding | tolerated(0.22) | benign(0) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
| SHISA6 | SNV | Missense_Mutation | c.1211C>T | p.Pro404Leu | p.P404L | Q6ZSJ9 | protein_coding | tolerated(0.1) | benign(0.003) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SHISA6 | SNV | Missense_Mutation | rs549533522 | c.1541N>T | p.Thr514Met | p.T514M | Q6ZSJ9 | protein_coding | deleterious(0.02) | probably_damaging(0.966) | TCGA-AZ-6601-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| SHISA6 | SNV | Missense_Mutation | c.614N>T | p.Pro205Leu | p.P205L | Q6ZSJ9 | protein_coding | tolerated(0.06) | probably_damaging(0.951) | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SHISA6 | SNV | Missense_Mutation | c.1307C>A | p.Pro436His | p.P436H | Q6ZSJ9 | protein_coding | deleterious(0) | possibly_damaging(0.794) | TCGA-AF-2690-01 | Colorectum | rectum adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| SHISA6 | SNV | Missense_Mutation | novel | c.492N>T | p.Glu164Asp | p.E164D | Q6ZSJ9 | protein_coding | tolerated(1) | benign(0.04) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |